Oscar Soto Raices, MD
Rheumatology · San Juan, PRNPI 1962441717
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Lilly USA, LLC at 50.2% of the total. Reporting peaked in 2019 at $140,344 and has fallen 93.3% since, to $9,352 in 2025. Among rheumatology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 720 payments — averaging $488.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$177K
- AbbVie$41K
- UCB, Inc.$30K
- GSK$28K
- Genentech USA, Inc.$16K
- Pfizer$15K
- plus $45K from 22 others
Across 370 payments — averaging $7616.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$1.7M
- AbbVie$893K
- Janssen Research & Development, LLC$67K
- Eli Lilly$59K
- E.r. Squibb & Sons, L.L.C.$28K
- Gilead$19K
- plus $13K from 2 others
What the payments were for
- Consulting fees$84,74524%
- Speaking & faculty fees$206,31959%
- Travel & lodging$39,86911%
- Food & beverage$20,7456%
- Education$2460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 292 | $176,673 |
| AbbVie | 88 | $40,517 |
| UCB, Inc. | 62 | $29,762 |
| GSK | 30 | $28,462 |
| Genentech USA, Inc. | 17 | $16,211 |
| Pfizer | 13 | $15,106 |
| E.r. Squibb & Sons, L.L.C. | 28 | $13,319 |
| Merck | 12 | $8,458 |
| Eli Lilly Export S.A. Puerto Rico Branch | 33 | $8,144 |
| Amgen(2 entities) | 38 | $5,196 |
| Johnson & Johnson(2 entities) | 16 | $3,027 |
| Pfizer Pharmaceuticals LLC | 3 | $1,748 |
| Eli Lilly | 7 | $958 |
| AstraZeneca | 15 | $847 |
| Bristol Myers Squibb | 4 | $704 |
| Novartis | 12 | $600 |
| PBG Puerto Rico LLC | 13 | $562 |
| Sanofi | 8 | $377 |
| Mallinckrodt Hospital Products Inc. | 5 | $343 |
| Sanofi-aventis U.S. LLC | 2 | $167 |
| Genentech, Inc. | 2 | $160 |
| Boehringer Ingelheim | 6 | $138 |
| Sobi, Inc | 1 | $100 |
| Organon | 6 | $100 |
| Gilead | 1 | $89 |
| ANI Pharmaceuticals, Inc. | 3 | $82 |
| EMD Serono, Inc. | 2 | $44 |
| Mallinckrodt Enterprises LLC | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$351,924 in reported general payments places this provider in the 95th percentile of 88 rheumatology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cimzia (2 Pack)Certolizumab Pegol | 41 | $260,551 |
| Humira(Cf) PenAdalimumab | 36 | $248,981 |
| Taltz AutoinjectorIxekizumab | 36 | $247,828 |
| RinvoqUpadacitinib | 32 | $208,088 |
| ProliaDenosumab | 63 | $110,194 |
| Cosentyx Sensoready PenSecukinumab | 14 | $104,878 |
| Enbrel SureclickEtanercept | 14 | $102,842 |
| Actemra ActpenTocilizumab | 18 | $84,447 |
| OtezlaApremilast | 12 | $57,664 |
| MethotrexateMethotrexate Sodium | 321 | $5,869 |
| Hydroxychloroquine Sulfate | 48 | $2,146 |
| Gabapentin | 194 | $2,103 |
| Pregabalin | 40 | $2,084 |
| SynthroidLevothyroxine Sodium | 12 | $1,492 |
| Prednisone | 132 | $1,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Cimzia (2 Pack) | $29,762 | $260,55141 claims |
| AbbVieRinvoq, Synthroid | $40,517 | $209,58044 claims |
| AmgenProlia, Otezla | $5,196 | $167,85975 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 88 rheumatology providers in Puerto Rico.
Other rheumatology in San Juan
- Radames Sierra ZoritaSan Juan$428K
- Yvonne FontSan Juan$193K
- Paloma AlejandroSan Juan$33K
- Grissel RiosSan Juan$13K
- Irma Vazquez-SanabriaSan Juan$10K
- Ariana Gonzalez-MelendezSan Juan$9K
- Ricardo Gago PineroSan Juan$7K
- Maria RecurtSan Juan$6K
- Valerie Marrero PereaSan Juan$5K
- Sari Pomales OrsiniSan Juan$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.